1. Home
  2. PHAR vs MEG Comparison

PHAR vs MEG Comparison

Compare PHAR & MEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • MEG
  • Stock Information
  • Founded
  • PHAR 1988
  • MEG 2012
  • Country
  • PHAR Netherlands
  • MEG United States
  • Employees
  • PHAR N/A
  • MEG N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • MEG Professional Services
  • Sector
  • PHAR Health Care
  • MEG Consumer Discretionary
  • Exchange
  • PHAR Nasdaq
  • MEG Nasdaq
  • Market Cap
  • PHAR 707.9M
  • MEG 764.0M
  • IPO Year
  • PHAR N/A
  • MEG 2020
  • Fundamental
  • Price
  • PHAR $10.96
  • MEG $20.51
  • Analyst Decision
  • PHAR Strong Buy
  • MEG Buy
  • Analyst Count
  • PHAR 3
  • MEG 5
  • Target Price
  • PHAR $30.00
  • MEG $31.80
  • AVG Volume (30 Days)
  • PHAR 5.3K
  • MEG 277.9K
  • Earning Date
  • PHAR 07-31-2025
  • MEG 08-06-2025
  • Dividend Yield
  • PHAR N/A
  • MEG N/A
  • EPS Growth
  • PHAR N/A
  • MEG N/A
  • EPS
  • PHAR N/A
  • MEG N/A
  • Revenue
  • PHAR $339,836,000.00
  • MEG $718,904,000.00
  • Revenue This Year
  • PHAR $12.88
  • MEG $10.49
  • Revenue Next Year
  • PHAR $8.54
  • MEG $7.12
  • P/E Ratio
  • PHAR N/A
  • MEG N/A
  • Revenue Growth
  • PHAR 22.44
  • MEG 10.92
  • 52 Week Low
  • PHAR $6.73
  • MEG $10.51
  • 52 Week High
  • PHAR $12.61
  • MEG $34.56
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 58.06
  • MEG 38.11
  • Support Level
  • PHAR $9.54
  • MEG $22.53
  • Resistance Level
  • PHAR $10.46
  • MEG $23.88
  • Average True Range (ATR)
  • PHAR 0.37
  • MEG 1.07
  • MACD
  • PHAR 0.10
  • MEG -0.22
  • Stochastic Oscillator
  • PHAR 81.20
  • MEG 1.46

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About MEG Montrose Environmental Group Inc.

Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, remove contaminant or create biogas. United States Contributes the majority of geographic revenue.

Share on Social Networks: